<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397978</url>
  </required_header>
  <id_info>
    <org_study_id>S63789</org_study_id>
    <nct_id>NCT04397978</nct_id>
  </id_info>
  <brief_title>Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases</brief_title>
  <acronym>LAT-MUM</acronym>
  <official_title>Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the quality of life (QOL) and to report on toxicity and outcome parameters after
      the (repeated) use of local ablative therapy (LAT) i.e. stereotactic radiotherapy (SRT) for
      patients with multiple (4-10) brain metastases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV prospective non-randomized observational trial (registry trial) for patients with a
      DS-GPA &gt; 1.5 or an estimated life expectancy of &gt;3 months and an established diagnosis on
      dedicated brain MRI of 4-10 BM of any solid primary tumor.

      We plan to deliver a local ablative therapy (LAT) i.e. SRT in 1 to 5 fractions on visible BM
      and post-surgical cavities if applicable.

      Our primary aim is to provide quality of life (QOL) data and our secondary aim is to report
      on several toxicity and outcome parameters for this patient cohort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the EQ-5D-5L questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the QLQ-BN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the PRO-CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the QLQ-BN20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the PRO-CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Time from SRT until local progression or death whichever comes first, up to 3 years after LAT</time_frame>
    <description>Local control of the irradiated metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from SRT until the occurrence of new brain metastases or death whichever comes first, up to 3 years after LAT</time_frame>
    <description>Brain metastasis free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from SRT until death from any cause</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>From baseline to ≤ 90 days after radiotherapy</time_frame>
    <description>Acute toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>From &gt; 90 days after radiotherapy through study completion</time_frame>
    <description>Late toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>Change in toxicity measured from baseline up to 3 years after radiotherapy</time_frame>
    <description>Occurrence of radionecrosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>Local ablative therapy with SRT</description>
    <other_name>SRT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with an established diagnosis on dedicated brain magnetic resonance (MRI) of
        4-10 brain metastases (BM) of any solid tumor with an estimated life expectancy of &gt;3
        months or a disease specific grade prognostic index (DS-GPA) of ≥ 1.5.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, ≥ 18 years of age

          2. Minimal 4 and up to a maximum of 10 synchronous BM diagnosed on a high resolution
             contrast-enhanced MRI scan (T1 gadolinium) not dated more than 4 weeks prior to
             inclusion.

          3. Maximal lesion diameter of single gross tumor volume (GTV) of 3 cm

          4. Maximal cumulative GTV (+CTV for cavity) of 30cm3

          5. Karnofsky performance status ≥ 70

          6. DS-GPA or expected overall survival (if no DS-GPA applicable) of ≥ 1.5 or &gt;3 months
             respectively.

          7. Any solid primary tumour. Lymphoma, germ cell tumor, small cell lung carcinoma and
             multiple myeloma are excluded.

          8. Ability to provide written informed consent and to participate in the procedure of the
             questionnaires.

        Exclusion Criteria:

          1. BM not amenable to SRT

          2. Previous SRT or surgery on the same lesion

          3. Co-morbidities considered clinically precluding the safe use of an MRI examination or
             SRT

          4. Any psychological, sociological or geographical issue potentially hampering compliance
             with the study

          5. Pregnancy

          6. Concurrent use of systemic therapy

          7. More than 10 BM on planning-MRI

          8. Maximum cumulative GTV (+CTV for cavity) of more than 30cm3 on planning-MRI

          9. A brainstem metastasis with a PTV of more than 20 cm3

         10. Leptomeningeal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Berkovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maarten Lambrecht, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Oldenburger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>An Nulens</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lien Smets, BA</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Berkovic, MD</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>Patrick.berkovic@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deveny Vanrusselt, BA</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>deveny.vanrusselt@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Berkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maarten Lambrecht, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Oldenburger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Nulens, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lien Smets, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deveny Vanrusselt, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiotherapy</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Multiple (4-10)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

